Cancer-Killing New Drug Candidate Utilizing AI to Enhance FDA Investigational New Drug Research
21 Mayo 2024 - 6:50AM
Business Wire
U.S. Precision Medicine, Inc. (USPM), a biopharma company
developing novel cancer therapeutics, today announced it will use
state-of-the-art artificial intelligence (AI) technology to bolster
independent research that has proven the company’s small molecule
candidate is highly effective in killing breast cancer.
U.S. Precision Medicine’s new cancer drug candidate has
demonstrated the ability to reduce tumor weight and volume by 85%
in just 30 days of treatment with no toxicity. The findings were
corroborated in the independent Investigational New Drug (IND)
research with small animal studies required by the FDA. The
company’s contract research organization currently is developing
the dosing plan and expanding the research to include an additional
100 cancer types, for which patents or patents pending are
held.
"Now that the validity of AI in pharmaceutical drug development
is gaining traction, we plan to conduct a comparative study
leveraging AI platforms in parallel with our ongoing IND research
to prepare for human clinical trials," said Frederick Fey,
co-founder and CEO of USPM.
“The drug candidate shows great promise as a treatment for most,
if not all, solid tumor cancers, which account for approximately 90
percent of adult cancers and 30 percent of all pediatric
cancers.”
The worldwide incidence of cancer continues to rise, with the
American Cancer Society projecting a 77% increase in new cases by
2050 versus 2022 levels. Last year, there were approximately 20
million new cancer diagnoses and 9.7 million cancer deaths
globally.
"Cancer represents a tremendous unmet medical need that is
projected to reach $200 billion by 2025 for cancer drugs alone,"
said Christopher Fey, co-founder and COO of USPM. "My brother and I
are passionate about turning cancer victims into survivors because
our father passed away from colon cancer at age 29 when we were
toddlers. We hope others will join us in improving outcomes for
patients across all cancer types."
U.S. Precision Medicine, Inc. (USPM) is a biopharma company that
identifies and validates promising, patented small molecule cancer
drug candidates from academic institutions, with the goal of
licensing them to pharmaceutical companies to improve patient
outcomes. USPM confirms drug efficacy and advances candidates with
the greatest potential through the FDA's Investigational New Drug
process and Phase 1 clinical trials to build value ahead of
potential partnering or M&A transactions.
For more information, please visit
www.USPrecisionMedicine.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521888891/en/
Kathryn Fleming kathy@starmarcomm.com 386-628-7955